Brief: Argenx Presents New Data Highlighting Phase 2 Results In Myositis And Sjogren’S Disease
10/06/2025 23:14
June 10 (Reuters) - argenx SE ARGX.BR: ARGENX PRESENTS NEW EFGARTIGIMOD DATA AT EULAR 2025 HIGHLIGHTING POSITIVE PHASE 2 PROOF-OF-CONCEPT RESULTS IN MYOSITIS AND SJOGREN’S DISEASE Source text: ID:nGNX7mQV3G Further company coverage: ARGX.BR (((( Reuters.briefs@thomsonreuters.com ;));))
Recent news on argenx SE
See all newsArgenx falls after Vyvgart trial update on myositis drug, brokers remain positive
Brief: ArgenX Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit In Myositis And Sjogren’S Disease
Brief: argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
Brief: Argenx Q1 Total Operating Income USD 1.313 Bln
Netherlands' Argenx Q1 net sales rise 63%, profit more than doubles